Disposition of two highly permeable drugs in the upper gastrointestinal lumen of healthy adults after a standard high-calorie, high-fat meal
article
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
This study investigated the disposition of two highly permeable drugs within the upper gastrointestinal tract of healthy adults following the ingestion of a standard high-calorie, high-fat meal.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
ObjectivesTo quantify the presence of two model highly permeable drugs, paracetamol and danazol, in the upper gastrointestinal lumen under conditions simulating the situation after disintegration of immediate release dosage forms administered in bioavailability/bioequivalence studies in the fed state. To understand the drug transfer process from the antral contents through the upper small intestine based on luminal drug data.Methods8 healthy male adult volunteers participated in a randomized, single dose, two-phase, crossover study. After evaluating the impact of homogenization on meal's viscosity and particle size, the meal, containing phenol red as non-absorbable marker, was administered to the antrum via the gastric lumen of a naso-gastro-intestinal tube. The drugs were administered in solution form (Phase I) and in suspension form (Phase II) with a glass of tap water to the antrum of the stomach, 30 min after the initiation of meal administration. Samples were aspirated from the antrum and the upper small intestine up to 4 hours post drug administration.ResultsApparent concentrations in the aqueous contents of the antrum were higher than apparent concentrations in the micellar contents of the upper small intestine for paracetamol; the opposite was observed for danazol. Based on total drug amount per volume data in contents of the upper gastrointestinal lumen, the transfer of paracetamol (aqueous solution or suspension) and danazol (aqueous suspension) through the upper small intestine could be described as an apparent first-order process. Transfer of a long-chain triglyceride solution of danazol was highly variable.ConclusionsConcentrations in the aqueous/micellar phase of luminal contents and values of parameters controlling the transfer from bulk gastric contents through the upper small intestine after a high-calorie, high-fat meal, were reported for the first time for highly permeable drugs. Data are expected to enhance the development of biorelevant in vitro and physiologically based biopharmaceutics modelling methodologies.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
- Luminal Lipid Phases after Administration of a Triglyceride Solution of Danazol in the Fed State and Their Contribution to the Flux of Danazol Across Caco-2 Cell Monolayers 2012
- In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media 2005
Cited by (1)
References (38)
- In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media via openalex
- Luminal Lipid Phases after Administration of a Triglyceride Solution of Danazol in the Fed State and Their Contribution to the Flux of Danazol Across Caco-2 Cell Monolayers via openalex
- doi:10.1172/jci107226 via openalex
- doi:10.1007/s11095-005-8476-1 via openalex
- doi:10.1208/s12248-019-0380-4 via openalex
- doi:10.1152/ajpgi.1985.249.5.g580 via openalex
- doi:10.1016/0378-5173(83)90018-2 via openalex
- doi:10.1023/a:1011958400362 via openalex
- doi:10.1007/s11095-011-0506-6 via openalex
- W1441769318 via openalex
- doi:10.1016/0016-5085(83)90382-7 via openalex
- doi:10.1002/jps.2600690525 via openalex
- W6674403076 via openalex
- W6771912324 via openalex
- doi:10.1016/0378-5173(84)90091-7 via openalex
- doi:10.1111/j.1365-2982.2006.00759.x via openalex
- doi:10.1016/s0731-7085(03)00246-2 via openalex
- doi:10.1016/s0016-5085(76)80010-8 via openalex
- doi:10.1211/0022357023367 via openalex
- doi:10.1021/mp500022u via openalex
- doi:10.1016/0016-5085(90)91150-5 via openalex
- doi:10.1016/j.ejps.2014.01.009 via openalex
- doi:10.1016/j.ejps.2016.05.013 via openalex
- doi:10.4333/kps.2004.34.3.223 via openalex
- doi:10.1023/a:1026155822121 via openalex
- doi:10.1002/jps.20477 via openalex
- doi:10.1080/00365520600610451 via openalex
- doi:10.1002/jps.2600581117 via openalex
- doi:10.1007/bf02233563 via openalex
- doi:10.1136/gut.16.10.777 via openalex
- doi:10.1021/acs.molpharmaceut.8b00865 via openalex
- doi:10.1093/ajhp/38.9.1400 via openalex
- doi:10.1016/j.ejpb.2008.05.011 via openalex
- doi:10.3390/ijms160612871 via openalex
- doi:10.1016/j.ejps.2015.11.012 via openalex
- doi:10.1016/s0016-5085(82)80140-6 via openalex
- doi:10.7326/0003-4819-94-6-826_2 via openalex
- doi:10.1023/a:1007568900147 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-05-11T06:51:31.497383+00:00
License: CC0
· commercial use OK